213 related articles for article (PubMed ID: 22547204)
1. Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids.
Zou H; Yuan C; Dong L; Sidhu RS; Hong YH; Kuklev DV; Smith WL
J Lipid Res; 2012 Jul; 53(7):1336-47. PubMed ID: 22547204
[TBL] [Abstract][Full Text] [Related]
2. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer.
Dong L; Vecchio AJ; Sharma NP; Jurban BJ; Malkowski MG; Smith WL
J Biol Chem; 2011 May; 286(21):19035-46. PubMed ID: 21467029
[TBL] [Abstract][Full Text] [Related]
3. Different Fatty Acids Compete with Arachidonic Acid for Binding to the Allosteric or Catalytic Subunits of Cyclooxygenases to Regulate Prostanoid Synthesis.
Dong L; Zou H; Yuan C; Hong YH; Kuklev DV; Smith WL
J Biol Chem; 2016 Feb; 291(8):4069-78. PubMed ID: 26703471
[TBL] [Abstract][Full Text] [Related]
4. Interactions of 2-O-arachidonylglycerol ether and ibuprofen with the allosteric and catalytic subunits of human COX-2.
Dong L; Zou H; Yuan C; Hong YH; Uhlson CL; Murphy RC; Smith WL
J Lipid Res; 2016 Jun; 57(6):1043-50. PubMed ID: 27059979
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of Cyclooxygenase Homodimers.
Yuan C; Sidhu RS; Kuklev DV; Kado Y; Wada M; Song I; Smith WL
J Biol Chem; 2009 Apr; 284(15):10046-55. PubMed ID: 19218248
[TBL] [Abstract][Full Text] [Related]
6. Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer.
Dong L; Sharma NP; Jurban BJ; Smith WL
J Biol Chem; 2013 Oct; 288(40):28641-55. PubMed ID: 23955344
[TBL] [Abstract][Full Text] [Related]
7. Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit.
Dong L; Yuan C; Orlando BJ; Malkowski MG; Smith WL
J Biol Chem; 2016 Dec; 291(49):25641-25655. PubMed ID: 27756840
[TBL] [Abstract][Full Text] [Related]
8. Interactions of fatty acids, nonsteroidal anti-inflammatory drugs, and coxibs with the catalytic and allosteric subunits of cyclooxygenases-1 and -2.
Smith WL; Malkowski MG
J Biol Chem; 2019 Feb; 294(5):1697-1705. PubMed ID: 30710016
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids.
Sharma NP; Dong L; Yuan C; Noon KR; Smith WL
Mol Pharmacol; 2010 Jun; 77(6):979-86. PubMed ID: 20194532
[TBL] [Abstract][Full Text] [Related]
10. Phospholipid actions on PGHS-1 and -2 cyclooxygenase kinetics.
Rand Doyen J; Yucer N; Lichtenberger LM; Kulmacz RJ
Prostaglandins Other Lipid Mediat; 2008 Mar; 85(3-4):134-43. PubMed ID: 18201917
[TBL] [Abstract][Full Text] [Related]
11. Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1.
Liu W; Poole EM; Ulrich CM; Kulmacz RJ
Pharmacogenet Genomics; 2012 Jul; 22(7):525-37. PubMed ID: 22513397
[TBL] [Abstract][Full Text] [Related]
12. Partnering between monomers of cyclooxygenase-2 homodimers.
Yuan C; Rieke CJ; Rimon G; Wingerd BA; Smith WL
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6142-7. PubMed ID: 16606823
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
14. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1.
Rimon G; Sidhu RS; Lauver DA; Lee JY; Sharma NP; Yuan C; Frieler RA; Trievel RC; Lucchesi BR; Smith WL
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):28-33. PubMed ID: 19955429
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity of guava leaf extract via inhibition of prostaglandin endoperoxide H synthase isoforms.
Kawakami Y; Nakamura T; Hosokawa T; Suzuki-Yamamoto T; Yamashita H; Kimoto M; Tsuji H; Yoshida H; Hada T; Takahashi Y
Prostaglandins Leukot Essent Fatty Acids; 2009; 80(5-6):239-45. PubMed ID: 19457650
[TBL] [Abstract][Full Text] [Related]
16. The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors.
Rieke CJ; Mulichak AM; Garavito RM; Smith WL
J Biol Chem; 1999 Jun; 274(24):17109-14. PubMed ID: 10358065
[TBL] [Abstract][Full Text] [Related]
17. On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1.
Burde T; Rimon G
Eur J Pharmacol; 2002 Oct; 453(2-3):167-73. PubMed ID: 12398900
[TBL] [Abstract][Full Text] [Related]
18. Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol.
Johnson AR; Marletta MA; Dyer RD
Biochemistry; 2001 Jun; 40(25):7736-45. PubMed ID: 11412128
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin endoperoxide H synthases: peroxidase hydroperoxide specificity and cyclooxygenase activation.
Liu J; Seibold SA; Rieke CJ; Song I; Cukier RI; Smith WL
J Biol Chem; 2007 Jun; 282(25):18233-18244. PubMed ID: 17462992
[TBL] [Abstract][Full Text] [Related]
20. Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases.
Liu W; Cao D; Oh SF; Serhan CN; Kulmacz RJ
FASEB J; 2006 Jun; 20(8):1097-108. PubMed ID: 16770009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
